Navigation Links
ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Date:9/8/2008

Preclinical Pharmacokinetic Data to be Presented at the 7th International

Symposium on Uveitis in Germany

ZURICH, Switzerland, Sept. 8 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced that the company has successfully completed its Phase I clinical study of the company's lead product candidate, ESBA105, in ophthalmic indications. In April 2008, ESBATech initiated the Phase I study designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers. This trial was conducted as a single and repeated dose escalation study in Switzerland. ESBA105 is a single-chain antibody fragment directed against TNF-alpha, and it is being developed initially for ophthalmic indications. Several additional clinical studies are in the preparation stages.

Manfred Zierhut, Professor in the Department of Ophthalmology at the University of Tuebingen in Germany, will present preclinical pharmacokinetic data on ESBA105 on Friday, September 12, 2008, at the 7th International Symposium on Uveitis in Constance, Germany. For more information on the symposium and on Prof. Zierhut's abstract, please visit http://www.iusg2008.org/.

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, commented, "The completion of this Phase I study with ESBA105 in ophthalmic indications marks a critical clinical milestone for the company. Recently, ESBATech secured CHF 23M (USD 22M) in an extended Series B venture financing round. This financing will fund further clinical studies with ESBA105 in ophthalmic indications, as well as build broad franchises in ophthalmology, rheumatology and respiratory diseases for ESBA105 and other antibody fragments. We look forward to announcing the results of this Phase I study and future clinical trials."

Peter Lichtlen, M.D., Ph.D., Hea
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ESBATechs Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops
2. Immureboost Inc Announces a Change of Name to Fountain Healthy Aging Inc
3. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
4. MedQuist Announces Additions to Board of Directors
5. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
6. Martek Announces Third Quarter 2008 Financial Results
7. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
8. China Bio Energy Holdings Group Announces Participation in the Susquehanna Second Annual Beijing Management Summit
9. American Oriental Bioengineering Announces Participation in September Investor Conferences
10. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
11. Mindray Medical International Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Oro Valley, Arizona (PRWEB) September 16, 2014 ... company that develops safe and effective products to ... through the use of a proprietary SPACEā„¢ Technology ... Executive Officer and President will present at the ... 18, 2014 at the Hyatt Regency Phoenix. ...
(Date:9/16/2014)... 2014  Ascendis Pharma A/S, a biotechnology company ... significant unmet medical needs, today announced positive interim ... to evaluate once-weekly TransCon Growth Hormone in children ... interim results will be presented at the 7th ... being held October 15-18, 2014, in Singapore.  ...
(Date:9/16/2014)... Canada (PRWEB) September 16, 2014 According ... the Toronto affiliate of ITRA Global, new development in ... the Toronto city council approving another 755 storeys of ... it appears construction cranes will be dominating the Toronto ... seems to have an unquenchable thirst for new development. ...
(Date:9/15/2014)... , Sept. 15, 2014   Global ... innovator of scientific products and services for satellite ... Acquisition Solution for Integrated Services (OASIS) from the ... GST was selected to provide the government best-value ... Small Business (SB) category in Pool 4. The ...
Breaking Biology Technology:Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3
... results in physician,s office -, MADISON, N.J., ... Quest Diagnostics Incorporated (NYSE: DGX ),today announced ... T(TM) fecal,immunochemical test, a point-of-care version of the ... the sensitivity and,specificity of the laboratory-based InSure FIT ...
... Announces CE Mark Approval for First Product, the CorMatrix ... ECM(TM) for ... an,Atlanta- based company dedicated to developing and delivering unique,extracellular matrix ... damaged cardiovascular tissue, announced,today that the company has received 510(k) ...
... Pursues Strategy of Reducing Heart Attack Deaths by Shielding ... High-Risk Plaques ... Prescient Medical, Inc., a,privately held medical device company dedicated ... results on the chemical,characterization and treatment of rupture-prone or ...
Cached Biology Technology:Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 2Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 3Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 4Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 5CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 2CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 3CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 4Prescient Medical, Inc. to Present Data on Identification and Treatment of Rupture-Prone Coronary Plaques at EuroPCR 2008 2
(Date:9/16/2014)... year, a new football season and another commercial cargo ... Dragon spacecraft is scheduled to blast off to the ... the company,s fourth contracted mission to the complex. , ... of research investigations sponsored by the Center for the ... of managing the U.S. National Laboratory on the space ...
(Date:9/16/2014)... A complex web of interaction between viruses, bacteria, ... by a growing international collaboration between Matthew Sullivan, ... of Ecology and Evolutionary Biology and Steven Hallam ... Canada. , "Bacteria are drivers of nutrient ... said. "As the climate is changing, so are ...
(Date:9/16/2014)... (KXL) would likely increase oil sands extraction, according to ... non-profit organization Near Zero. The results are detailed in ... both supporters and opponents of the pipeline. ... to significantly higher greenhouse gas emissions, with the exact ... "This report examines three main scenarios discussed by participants ...
Breaking Biology News(10 mins):CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3Keystone XL would likely raise oil sands production and greenhouse gas emissions 2
... the University of California, Riverside are part of a ... living bacteria a discovery that could help in ... The research team believes this is the first ... biological rather than chemical means. It opens the door ...
... teaming up with colleagues in other higher education institutions ... courses. They include research into a mobile biosensor, ... sports, and a manufacturing process to make titanium golf ... seven collaborative studentships, currently underway in the East Midlands. ...
... a diesel engine is far from easy. Due to ... combustion cycles are the same. Furthermore, the measurements are ... is injected into the cylinder causes an extra source ... cylinder with an engine adapted for this purpose. ...
Cached Biology News:Nanotube-producing bacteria show manufacturing promise 2
... Plates are designed for quick and easy ... plates feature two 0.25mm holes laser cut ... The wells remain liquid-tight during incubation of ... time the protein diffuses from the gel ...
... is a direct antibiotic-based ... identification. Recombinant selection depends ... eliminating the need for ... quick and inexpensive process ...
... Enhancer does for enzyme-/substrate-based blotting what intensifying screens ... signal up to 10-fold (or one order of ... Blot Signal Enhancer membrane treatment is a simple, ... your current Western blotting protocol. The result is ...
... a multi-functional program that searches ... a sequence file for polymerase ... site-directed mutagenesis, and various hybridization ... and secondary structure of oligonucleotides ...
Biology Products: